![Andreas Gerber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andreas Gerber
Operationeel Directeur bij APEIRON Biologics AG
Actieve functies van Andreas Gerber
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Operationeel Directeur | 01-06-2021 | - |
Loopbaan van Andreas Gerber
Opleiding van Andreas Gerber
University of Basel | Doctorate Degree |
University of St. Gallen | Masters Business Admin |
Statistieken
Internationaal
Zwitserland | 3 |
Oostenrijk | 2 |
Operationeel
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectoraal
Consumer Services | 3 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Health Technology |
- Beurs
- Insiders
- Andreas Gerber
- Ervaring